Medical Breakthrough: First Integrated Sacral Neuromodulation (iSNM) System Approved, Offering New Hope for Urge Incontinence Patients

Jun 24, 2025 08:01 CST Updated 08:01

NeuSpera

Developer of Implantable Medical Devices

Urgency Urinary Incontinence: An Overlooked Life Disruption

In daily life, have you ever experienced a moment when you suddenly felt an intense urge to urinate, but before you could make it to the toilet, urine leaked out uncontrollably? This embarrassing situation is likely caused by urgency urinary incontinence (UUI).

Urgency Urinary Incontinence, as a major component of overactive bladder, severely impacts patients’ quality of life. Imagine being in an important business meeting, at a warm gathering with friends, or in a quiet movie theater, when a sudden, overwhelming urge to urinate forces you to rush out. The resulting embarrassment and distress can plunge patients into deep social anxiety. Many patients consequently avoid traveling long distances or participating in social activities; even simple walks or shopping trips become luxuries, causing their world to shrink ever smaller.

Such a distressing condition is not merely an “unspeakable secret” suffered by a few individuals. Statistics indicate that approximately one in five women in the United States is afflicted by it. In China, although large-scale epidemiological data are currently lacking, clinical experience suggests that the number of patients with urgency urinary incontinence (UUI) is significant. Like a hidden “lifestyle killer,” it silently erodes patients’ quality of life, inflicting both physical and psychological torment. For a long time, UUI patients have had to weigh the benefits of traditional sacral neuromodulation (SNM) therapy against genuine concerns about complications related to implanted batteries and the need for surgical replacement. Today, the approval of the NeuSpera iSNM system has undoubtedly brought new hope to these patients. So, what makes this highly anticipated system so remarkable?

Medical Breakthrough: NeuSpera iSNM System Approved

On June 18, 2025, the U.S. Food and Drug Administration (FDA) officially approved NeuSpera Medical, Inc.’s integrated Sacral Neuromodulation (iSNM) System for the treatment of Urgent Urinary Incontinence (UUI). This approval brings new hope to countless patients suffering from UUI and marks the dawn of a new era in the treatment of this condition.

For a long time, although traditional sacral neuromodulation (SNM) therapy has been able to alleviate symptoms in patients with urgency urinary incontinence (UUI) to some extent, the various issues associated with implanted batteries have deterred many patients. The emergence of NeuSpera’s iSNM system is undoubtedly a welcome development, offering UUI patients a novel and superior alternative that completely breaks through the limitations of traditional therapies. With this system, patients no longer need to endure the discomfort of an implanted battery or worry about the risks and pain associated with surgical battery replacements. This innovative breakthrough represents not only an advancement in medical technology but also a profound commitment to improving patients’ quality of life, providing strong support for them to regain their confidence and dignity.

Innovative Technology, Bringing New Hope

(I) The Principles Revealed

The Neuspera iSNM system has generated significant excitement in the field of UUI treatment, largely due to its innovative technology. This system delivers all the functionalities of traditional SNM within a highly advanced form factor, operating like an intricate medical “dance,” with each step showcasing the allure of technological innovation.

In this system, a smart, miniaturized neurostimulator is first precisely implanted near the sacral nerve. This miniature neurostimulator acts as a compact yet powerful “signal commander”; despite its small size, it delivers substantial power. It utilizes advanced materials and manufacturing processes to ensure stable and safe operation within the human body. Its size and shape are meticulously designed not only to facilitate implantation but also to minimize impact on surrounding tissues.

The task of initiating therapy is delegated to an external treatment pad worn on the lower back. This pad may appear ordinary, but it conceals sophisticated technology. Acting as the “energy envoy” for the neurostimulator, it operates for only about two hours each day to deliver the energy and signals required to activate the treatment program. When not in use, the pad can be wirelessly charged like a smartphone, offering convenience and significantly enhancing the patient experience. The application of this wireless charging technology not only eliminates the constraints of traditional cables but also reduces the risk of infection associated with charging ports, thereby providing substantial convenience for patients’ daily lives.

(II) Clinical Data Speak

A six-month pivotal trial served as the “litmus test” for the efficacy of the NeuSpera iSNM System. In this trial, 128 courageous patients were among the first to receive NeuSpera’s iSNM therapy, pioneering the exploration of this innovative treatment. The trial results undoubtedly delivered a major surprise to all those focused on the treatment of urgency urinary incontinence (UUI).

Data show that 84.2% of patients experienced a reduction in urgent leakage of 50% or more, a rate comparable to, and in some respects even surpassing, those reported in recent sacral neuromodulation (SNM) studies. This indicates that the vast majority of treated patients experience significant symptom improvement, with previously frequent embarrassing incidents substantially reduced. Among responders, 84% were classified as “super-responders,” achieving a reduction in urgency urinary incontinence (UUI) symptoms of more than 75%. The emergence of these “super-responders” highlights the substantial potential of the NeuSpera iSNM System, which not only alleviates symptoms but also delivers a qualitative leap in patients’ quality of life.

Even more encouragingly, 42% of responding patients achieved complete “dryness,” representing a 100% reduction in UUI symptoms. This means that these patients were completely freed from the burden of UUI, regaining their confidence and dignity in daily life. They can now freely participate in various activities without constant worry about the embarrassment of urinary incontinence, bringing sunshine back into their lives. In addition to these direct improvements in symptom metrics, patients’ quality of life showed clinically significant improvement, increasing by 3.5-fold. The substantial reduction in voiding frequency and urgency episodes has made patients’ daily routines more regular and comfortable. No longer needing frequent trips to the restroom, they have experienced greatly improved sleep quality and a renewed sense of mental well-being. These clinical data serve as the most compelling evidence of the efficacy of the NeuSpera iSNM System, offering tangible hope to UUI patients and instilling great confidence in the future of UUI treatment.

A Promising Future: A New Chapter in UUI Treatment

The approval of the NeuSpera iSNM System is undoubtedly a significant milestone in the field of UUI treatment, bringing tangible benefits to patients and paving the way for future therapeutic advancements.

With the widespread adoption of this innovative system, we have reason to believe that an increasing number of patients with Urgent Urinary Incontinence (UUI) will benefit from it. No longer overshadowed by urinary incontinence, they will be able to freely enjoy the beauty of life once again. Whether participating in social activities, traveling, or engaging in daily work and study, they will no longer face restrictions, leading to a significant improvement in their quality of life.

CCI Cardiovascular Physicians Innovation Club

Long-press the QR code to follow us

This Issue's Feature: Shen Li

Responsible Editor: Chen Baolin

Author of this article: Yunyexuan

Post-Production: Zhang Lirong